Featured Research

from universities, journals, and other organizations

Scientists synthesize unique family of anti-cancer compounds

Date:
February 13, 2010
Source:
Yale University
Summary:
Scientists have streamlined the process for synthesizing a family of compounds with the potential to kill cancer and other diseased cells, and have found that they represent a unique category of anti-cancer agents.

Image of one of the kinamycin compounds synthesized by Yale researchers destroying ovarian cancer cells (the spherical objects) in less than 48 hours in lab tests.
Credit: Gil Mor

Yale University scientists have streamlined the process for synthesizing a family of compounds with the potential to kill cancer and other diseased cells, and have found that they represent a unique category of anti-cancer agents. Their discovery appears in this week's online edition of the Journal of the American Chemical Society.

The team studied a family of compounds known as the kinamycins, which are naturally produced by bacteria during metabolism and are known for their potent toxicity. For years scientists have guessed that a core structure common to the different compounds within the group was responsible for this toxicity. Until now, chemists could not study the core structure because there was no simple way to create it in the laboratory.

Now the Yale team has developed a new method to recreate this structure that allows them to synthesize the kinamycins with much greater efficiency than previously possible. While scientists have produced kinamycins in the laboratory in the past, the Yale team was able to halve the number of steps required to go from simple, easily obtainable precursors to the complete molecule -- from 24 down to 12.

"By shortening the synthesis we can now prepare these molecules in the quantities required for further studies, including animal studies and even clinical trials," said Seth Herzon, assistant professor of chemistry and lead author of the study.

Working with researchers at the Yale School of Medicine and the Yale Chemical Genomics Screening Facility, the team has begun testing several of the compounds against cancer cells, with promising preliminary results. Next, they will work to understand the exact mechanism that makes the compounds -- which are benign on their own -- highly toxic once they penetrate cells.

"The key to success will be whether we can develop selectivity -- whether we can kill cancer cells in the presence of non-cancerous tissue," Herzon said. "Based on what we already know about the chemical reactivity of these molecules, I'm optimistic we can do this."

The reactive core of the kinamycins also plays a key role in another compound the team is studying, called lomaiviticin A, which is even more toxic and could prove even more effective in destroying cancer cells. "Lomaiviticin A is the big fish. It's more potent than the kinamycins, but it's also much harder to synthesize," Herzon said.

Both the kinamycins and lomaiviticin A are unique in their toxicity profiles, Herzon said, representing a new category of anti-cancer agents.

"There's no close analogy to draw from to predict how these molecules will behave, which will make it especially interesting to see where this research takes us," Herzon said. "This research involves a lot of exciting chemistry, but it also has real applications in biology and human medicine."

Other authors of the study include Christina Woo, Liang Lu, Shivajirao Gholap and Devin Smith, all of Yale University.

Funding for this research was provided by Yale University and Eli Lilly.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christina M. Woo, Liang Lu, Shivajirao L. Gholap, Devin R. Smith and Seth B. Herzon. Development of a Convergent Entry to the Diazofluorene Antitumor Antibiotics: Enantioselective Synthesis of Kinamycin F. Journal of the American Chemical Society, 2010; 100208113952050 DOI: 10.1021/ja910769j

Cite This Page:

Yale University. "Scientists synthesize unique family of anti-cancer compounds." ScienceDaily. ScienceDaily, 13 February 2010. <www.sciencedaily.com/releases/2010/02/100212141106.htm>.
Yale University. (2010, February 13). Scientists synthesize unique family of anti-cancer compounds. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2010/02/100212141106.htm
Yale University. "Scientists synthesize unique family of anti-cancer compounds." ScienceDaily. www.sciencedaily.com/releases/2010/02/100212141106.htm (accessed October 23, 2014).

Share This



More Matter & Energy News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Chameleon Camouflage to Give Tanks Cloaking Capabilities

Chameleon Camouflage to Give Tanks Cloaking Capabilities

Reuters - Innovations Video Online (Oct. 22, 2014) — Inspired by the way a chameleon changes its colour to disguise itself; scientists in Poland want to replace traditional camouflage paint with thousands of electrochromic plates that will continuously change colour to blend with its surroundings. The first PL-01 concept tank prototype will be tested within a few years, with scientists predicting that a similar technology could even be woven into the fabric of a soldiers' clothing making them virtually invisible to the naked eye. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Jet Sales Lift Boeing Profit 18 Pct.

Jet Sales Lift Boeing Profit 18 Pct.

Reuters - Business Video Online (Oct. 22, 2014) — Strong jet demand has pushed Boeing to raise its profit forecast for the third time, but analysts were disappointed by its small cash flow. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Internet of Things Aims to Smarten Your Life

Internet of Things Aims to Smarten Your Life

AP (Oct. 22, 2014) — As more and more Bluetooth-enabled devices are reaching consumers, developers are busy connecting them together as part of the Internet of Things. (Oct. 22) Video provided by AP
Powered by NewsLook.com
What Is Magic Leap, And Why Is It Worth $500M?

What Is Magic Leap, And Why Is It Worth $500M?

Newsy (Oct. 22, 2014) — Magic Leap isn't publicizing much more than a description of its product, but it’s been enough for Google and others to invest more than $500M. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Space & Time

Matter & Energy

Computers & Math

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins